Immunomodulatory therapies for acute pancreatitis

Do incretin-based therapies cause acute pancreatitis?

In 2007 a question was raised about the causal relationship between the first of the glucagon-like peptide 1 receptor agonists, exenatide, and pancreatitis, as postmarketing reports of pancreatitis in patients treated with this agent had been received by the Food and Drug Administration (FDA). There had been six reports of hemorrhagic pancreatitis, with two of the cases resulting in death. An u...

The Immunomodulatory Effects and Mechanisms of Tim-3 Action in the Early Stage of Mice with Severe Acute Pancreatitis

Background: Tim-3 has been considered as an ideal target for the immunotherapy of inflammation, but it is unclear whether Tim-3 also plays an important role in acute pancreatitis (AP), as well. Objective: To identify the immunomodulatory effects and mechanisms of Tim-3 action in the early stages of severe acute pancreatitis in mice. Methods: Ma...

Acute Pancreatitis (AP) and Dietary Habbits

Inflammation of pancreatic parenchyma is said to be pancreatitis. It can be acute, presenting as emergency with short history or chronic as a continuation of acute with a long history. Autodigestion is responsible for pancreatitis on background of premature activation of pancreatic enzymes within the pancreas. Acute Pancreatitis is acute inflammation of the pancrease which can be mild to modera...

Stem Cell Therapies on Pancreatitis

Immunomodulatory therapies for sepsis: unexpected effects with macrolides.

Despite intensive efforts to increase our knowledge of the inflammatory pathways involved in the pathogenesis of sepsis, several clinical trials of agents aimed at modulating the immune response of the host, such as anti-endotoxin antibodies, anti-tumour necrosis factor (TNF) antibodies and soluble TNF receptors, have failed to disclose any definite clinical benefit. The same applies to the adm...